Sosei Group
Sosei is a Japanese biopharmaceutical company that develops and commercializes innovative drugs.
Business Model:
Revenue: $0
Employees: 11-50
Rankings
Industries / Tags:
Detailed Sosei Group Information
Geographic Data
Address:
City: Tokyo
State: Tokyo
Zip:
Country: Japan
Financial Info
Stage:
grant
Raised Last:
$0
Raised Total:$265M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Sosei Group Corporation is an international biopharmaceutical company originating from Japan that discovers and develops innovative biopharmaceuticals for the treatment of Alzheimer&s;s disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. By utilizing their platform technologies - GPCR structure-based drug design platform technology, peptide platform technologies and nanotechnology - they have established a product pipeline with first/best in class potential. Through development and commercialization partnerships they have already delivered three medicines to the market (two COPD bronchodilators and an emergency contraceptive), which generate significant and stable revenue streams that enable further growth.
Contact Phone:
Contact Email:
Sosei Group went public on 8/6/2004 on the TYO
Listed Exchange:
TYO
IPO Date:
8/6/2004
Ticker Symbol:
4565
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2017 | MiNA Therapeutics | Corporate Round | 0 |
| 11/2016 | JITSUBO | Venture Round | 0 |
| 5/2017 | MiNA Therapeutics | Corporate Round | 0 |
| 11/2016 | JITSUBO | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 12/2021 | Grant | - |
COVID-19 Therapeutics Accelerator COVID-19 Therapeutics Accelerator |
8/2003 | Series B | 6 | $13M |
Resona Capital Yasuda Enterprise Development Mitsui Global Investment JAFCO Japan Asia Investment Nomura Holdings Resona Capital Yasuda Enterprise Development Mitsui Global Investment JAFCO Japan Asia Investment Nomura Holdings |
3/2012 | Post-IPO Equity | 1 | - |
JAFCO JAFCO JAFCO JAFCO |
7/2020 | Post-IPO Debt | $200M | 9/2004 | Post-IPO Equity | 1 | $52M |
Scottish Equity Partners Scottish Equity Partners |
12/2021 | Grant | 1 | - |
COVID-19 Therapeutics Accelerator COVID-19 Therapeutics Accelerator |
3/2012 | Post-IPO Equity | 1 | - |
JAFCO JAFCO JAFCO JAFCO |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 2/2015 | Heptares Therapeutics | |
| 7/2005 | Arakis Limited |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
